JPS5992354A - Reagent for immune serological diagnosis - Google Patents

Reagent for immune serological diagnosis

Info

Publication number
JPS5992354A
JPS5992354A JP20349182A JP20349182A JPS5992354A JP S5992354 A JPS5992354 A JP S5992354A JP 20349182 A JP20349182 A JP 20349182A JP 20349182 A JP20349182 A JP 20349182A JP S5992354 A JPS5992354 A JP S5992354A
Authority
JP
Japan
Prior art keywords
latex
latex particles
reagent
penicillamine
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP20349182A
Other languages
Japanese (ja)
Other versions
JPH0145028B2 (en
Inventor
Michio Kuge
久下 倫生
Michiya Nakagawa
道也 中川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sekisui Chemical Co Ltd
Original Assignee
Sekisui Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sekisui Chemical Co Ltd filed Critical Sekisui Chemical Co Ltd
Priority to JP20349182A priority Critical patent/JPS5992354A/en
Publication of JPS5992354A publication Critical patent/JPS5992354A/en
Publication of JPH0145028B2 publication Critical patent/JPH0145028B2/ja
Granted legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PURPOSE:To obtain a reagent for immune serological diagnosis keeping high sensitivity for a long period and does not cause self-flocculating with a long time preservation, by adding penicillamine to latex suspension. CONSTITUTION:The titled reagent for immune serological diagnosis has special features that 250mug-5,000mug gamma-globulin is sensitized per 10mg latex particles having 0.08-0.80mum diameter and containing 0.08-2.0wt% said latex particles further 0.01-10wt% penicillamine is added to this suspension. As latex particle, for example, polystyrene or copolymer of a monomer having phenyl radical and an anionic monomer are suitable. Further, either D-, L- or DL- penicillamines can be used.

Description

【発明の詳細な説明】 本発明は免疫血清学的診断試薬に関する。[Detailed description of the invention] The present invention relates to immunoserological diagnostic reagents.

従来、ラテックス粒子を担体とし、抗原又は抗体を感作
させ、血清中の抗体もしく祉抗原と特具的に此、る抗原
、抗体反応によシラテックス粒子の凝集反応を生じさせ
、その結果L11重疾患の診断を行うことが免疫血清学
的診断法として臨床検査の分野において行なわれてお夛
、例えばリウマチ因子、HBs抗原、HBs抗体、抗ス
トレプトリジン−〇(ASO)、C−反応性蛋白償(C
RP)、α−フェトプロティン、癌胎児性抗Ai((c
aA)等の検査にもこのような免疫mBpy学的診断試
薬が用いられている。
Conventionally, latex particles are used as carriers, and antigens or antibodies are sensitized, and the agglutination reaction of the latex particles is caused by the antigen-antibody reaction specifically with antibodies or anti-antigens in serum. Diagnosis of L11 severe disease has been carried out in the field of clinical testing as an immunoserological diagnostic method, such as rheumatoid factor, HBs antigen, HBs antibody, anti-streptolysin-○ (ASO), C-reactivity. Protein compensation (C
RP), α-fetoprotein, oncofetal anti-Ai ((c
Such immunological diagnostic reagents for mBpy are also used for tests such as aA).

か\る診断試薬として、例えばポリスチレン粒子が分散
されているラテックス懸濁液中の、ポリスチレン粒子に
ガンマグロブリンを混合し粒子表面に吸着させた庵のが
一般に使用されてムる。このような診断試薬では、ガン
マグロブリンは溶液中でラテックス粒子に吸着されずに
存在する本のとラテックス表面上のものとが吸脱着して
平衡状態にある。そしてガンマグロブリンは主体がイム
ノグロブリンG(IIIG)であセ、ガンマグロブリン
中の90%以上を占めている。IIGは分子同志が会合
し2重体、Bfi体等の多久体を形成しやすいが、か\
る多久体はラテックス粒子t#集させる性質が強く、試
薬の経時変化をまねくおそれがある。
As such a diagnostic reagent, for example, a mixture of gamma globulin mixed with polystyrene particles and adsorbed onto the particle surface in a latex suspension in which polystyrene particles are dispersed is generally used. In such a diagnostic reagent, gamma globulin exists in an equilibrium state in which gamma globulin is adsorbed and desorbed between the book that is not adsorbed to the latex particles in solution and the gamma globulin that is on the latex surface. Gamma globulin is mainly composed of immunoglobulin G (IIIG), which accounts for more than 90% of gamma globulin. IIG molecules tend to associate with each other and form durable bodies such as double bodies and Bfi bodies, but
The long-lasting body has a strong tendency to collect latex particles t#, which may cause deterioration of the reagent over time.

このため例えば特開昭54−26327号公報ではラテ
ックス懸濁液中に塩化プリン、ナッカロースを加えるこ
とによシ経時変化を抑制している。しかし塩化コリン、
サッカ目−スを添加すると懸濁液の粘度上昇をきたしラ
テックス粒子の凝集反応に際しての感度の低下、すなわ
ち検出可能な測定対象物の濃度下限の上昇をきたし、又
凝集反応速度が低下する欠点が新たに生ずる。
For this reason, for example, in JP-A-54-26327, changes over time are suppressed by adding purine chloride and naccarose to a latex suspension. However, choline chloride,
Addition of saccharomyces causes an increase in the viscosity of the suspension, resulting in a decrease in sensitivity during the aggregation reaction of latex particles, that is, an increase in the lower limit of the concentration of the detectable analyte, and a decrease in the aggregation reaction rate. arise anew.

本発明はこのような欠点を解消し、ラテックス粒子のa
集反応に際しての感度が長期間に亘シ高感度に維持され
、長期間の保存によっても自己凝集が生じない免疫血清
学的診断試薬を提供することを目的とする。
The present invention eliminates these drawbacks and improves the a
The object of the present invention is to provide an immunoserological diagnostic reagent that maintains high sensitivity during aggregation reactions over a long period of time and does not cause self-aggregation even after long-term storage.

本発明の要旨は、粒径008μmから0.80μ雷のラ
テックス粒子toWg当シ、ガンマグロブリンが250
μノから50007jy感作されておシ、該ラテックス
粒子が0.08重1チから2.0重且チ含有されている
2テツクス懸濁腋からなシ、該懸濁液中に0.01重1
1チからto、ox員チのペニシラミンが添加されてい
ることを特徴とする、免反血清学的診11斤試薬に存す
る。
The gist of the present invention is to use latex particles toWg with a particle size of 008 μm to 0.80 μm, and gamma globulin of 250 μm.
50,007 days sensitized from 1 to 50,007 days, and the suspension contains 0.08 to 2.0 weight of the latex particles, and the suspension contains 0.01 to 2.0 weight of the latex particles. Heavy 1
The invention consists of an 11 loaf reagent for immunological serological diagnosis, characterized in that from 1 to 100% of penicillamine is added.

次に本発明免疫血清学的診断試薬について更に詳細に説
明する。
Next, the immunoserological diagnostic reagent of the present invention will be explained in more detail.

本発明におけるラテックス粒子の粒径は、008μmか
ら0.80μ飢の範囲にあるものが使用される。これは
、ラテックス粒子に感作されたガンマグロブリンが検体
中の抗原又は抗体と反応して凝集反応を生ずるとラテッ
クス粒子が数個乃至数十個くっついて凝集像を生ずるが
、これをガラス板上で肉眼判定したシ、光学的に散乱光
の変化でとらえたシ、透過光の強弱変化でとらえたシす
るに適肖な粒径範囲である。
The particle size of the latex particles used in the present invention ranges from 0.08 μm to 0.80 μm. This is because when gamma globulin sensitized to latex particles reacts with antigens or antibodies in the sample and causes an agglutination reaction, several to dozens of latex particles stick together and form an agglutinated image. This is a suitable particle size range for determining the particle size with the naked eye, optically detecting it by changes in scattered light, and detecting it by changing the intensity of transmitted light.

ジテックス粒子ケよ、全粒子が0.08μmから0.8
0μmの範囲に存在゛するものが好ましいが、凝集像に
影響を与えない程度の少l、望ましくは5チ以内でか\
る粒径から若干外れるものを含むことも詐容される。
Ditex particles, all particles are from 0.08 μm to 0.8
Preferably, it exists in the range of 0 μm, but it should be as small as not to affect the agglomerated image, preferably within 5 μm.
It is also falsified that the particle size slightly deviates from the specified particle size.

ラテックス粒子として袖、例えばポリスチレン粒子の他
、フェニル基を有する単量体と陰イオン性却量体との共
重合体粒子が好適である。
Suitable latex particles include, for example, polystyrene particles and copolymer particles of a monomer having a phenyl group and an anionic polymer.

共重合体粒子の場合、フェニル基を有する単量体トシて
Ll例えばスチレン、ジビニルベンゼン、エチルスチレ
ン、α−メチルスチレン等カ存し、又陰イオン性の単量
体としては、例えばスチレンスルホン酸塩、ジビニルベ
ンゼンスルホン酸塩、エチルスチレンスルホ/酸塩、α
−メチルスルホン酸塩等が存する。
In the case of copolymer particles, phenyl group-containing monomers such as styrene, divinylbenzene, ethylstyrene, α-methylstyrene, etc. are present, and anionic monomers include, for example, styrene sulfonic acid. salt, divinylbenzenesulfonate, ethylstyrene sulfonate/acid, α
-Methylsulfonate, etc.

又、前記の共重合体粒子を得るには、例えばフェニル基
を有する単量体100重量部と陰イオン性即駿体0.1
〜70重量部を乳化剤の不存在下に過硫酸塩を重合開始
剤として水中で共重合反応を生じさせることにょ〕得ら
れる。このようにして得られる共重合体粒子には、共重
合成分である陰イオン性単量体に基づくものと重合開始
剤の切片の陰イオンに基づく表面荷電が付与される。共
重合体粒子の表面荷電密度はラテックス懸濁液における
陰イオンの解離濃度で3.OX I Oモル/d 〜8
0. OX 10   モに/d  の範囲内に在する
ものとされ、が\る範囲内にある場合は、乳化剤が存在
しなくとも共重合体粒子間の自己凝集を防ぎ安定なラテ
ックスg濁液が得られる。
In addition, in order to obtain the above-mentioned copolymer particles, for example, 100 parts by weight of a monomer having a phenyl group and 0.1 parts by weight of an anionic monomer are added.
~70 parts by weight can be obtained by causing a copolymerization reaction in water using a persulfate as a polymerization initiator in the absence of an emulsifier. The copolymer particles thus obtained are given surface charges based on the anionic monomer as a copolymerization component and the anion of the polymerization initiator fragment. The surface charge density of the copolymer particles is determined by the dissociation concentration of anions in the latex suspension. OXIO mol/d ~8
0. OX10 is assumed to be within the range of /d, and if it is within the range of It will be done.

本発明においてはラテックス粒子10訊り当シ、ガンマ
グロブリンが250μりから5000 pf感作される
In the present invention, 250 μm to 5000 pf of gamma globulin is sensitized per 10 latex particles.

本発明においてラテックス粒子に感作されるガンマグロ
ブリンは、ガンマグロブリンそのものであってもよりし
、又11!iG分画であってもよいし、又更にはJGを
更に分画して得られる抗原又は抗体そのものであっても
よい。
In the present invention, the gamma globulin sensitized to latex particles may be gamma globulin itself, or 11! It may be an iG fraction, or it may be an antigen or antibody itself obtained by further fractionating JG.

例えil’ CRPを検出する場合において、JGを更
に分画し九F (a b’ )2 が使用されることK
よシRA因子の干渉や補体の妨害を除去することができ
る。この場合はF (s b’ )2の感作景が上記範
囲内に存在するものとされる。
For example, when detecting il' CRP, JG is further fractionated and 9F (ab')2 is used.
Interference with other RA factors and interference with complement can be removed. In this case, it is assumed that the sensitized scene of F (s b' )2 exists within the above range.

ガンマグロブリンの感作がラテックス粒子10’Vfi
!l7250μmから5000μタ とされるのは、2
50μmよシも少量では凝集速度が遅くなるし、凝集反
応を行った後の凝集像も検出し難くなシ、又5000μ
りよシ多量では系中に遊離して存在するガンマグロブリ
ンが多く反応するため、結局a集反応における感度低下
を来たしやすいからである。
Gamma globulin sensitization occurs with latex particles at 10'Vfi.
! 17250μm to 5000μm is 2
If the diameter is as small as 50 μm, the aggregation rate will be slow, and the aggregation image after the agglutination reaction will be difficult to detect.
This is because if the amount is too large, a large amount of gamma globulin free in the system reacts, which tends to result in a decrease in sensitivity in the a group reaction.

ラテックス懸濁液中に分散されているラテックス粒子の
量は0,08重′Mチから2,0重Jlチとされる。ラ
テックス粒子の量が上記範囲に存するようになされるの
は、ラテックス粒子の量が0.08重iqbよシも少量
では凝集反応を行なった後の凝集像の検出が困難となり
、又20重量−よシも多量では凝集反応によシ小級集が
多数化じこれかために凝集像の判定が困難になるからで
ある。
The amount of latex particles dispersed in the latex suspension ranges from 0.08 to 2.0 weight Jl. The amount of latex particles is kept within the above range because if the amount of latex particles is as small as 0.08 weight iqb, it becomes difficult to detect an agglomerated image after the agglutination reaction. This is because if the amount is too large, a large number of small groups will occur due to the agglutination reaction, which will make it difficult to judge the agglutination image.

本発明にtitラテックス懸濁液中にo、oxffiJ
tチから1000重量−のペニシラミンが添加されてい
る。ペニシラミンは、次式 %式% ) で表わされる含硫α−アミノ酸である。
In the present invention, tit o, oxffiJ in latex suspension.
1000 wt. of penicillamine was added from 100 ml. Penicillamine is a sulfur-containing α-amino acid represented by the following formula.

そしてペニシラミンは、IJGの会合を抑制し、ラテッ
クス診断試薬の感度低下を防ぐ働きを有することがわか
った。ベニシ2ξ/は0体、L体、DL体のいずれもが
使用で籾る。ペニシラミンの添加量は、2テツクス懸濁
液中に0.01重量%からxo、oi@チの範囲とされ
る。これは0.01重量%よりも少量ではIQGの会合
抑制や診断試薬として使用する際の感度低下を防ぐ働き
が発現されないおそれがあシ、又診断試薬として実際に
使用する際に薬表面や試薬の拡がシの端部が乾燥しやす
いがこの場合に溶解度との関係で結晶を生じやすいもの
となるので好ましくないことによる。
It was also found that penicillamine has the function of suppressing the association of IJG and preventing a decrease in the sensitivity of latex diagnostic reagents. Benishi 2ξ/ can be used in 0 body, L body, and DL body. The amount of penicillamine added in the 2tex suspension ranges from 0.01% by weight to xo, oi@chi. If the amount is less than 0.01% by weight, there is a risk that the effect of suppressing IQG association and preventing a decrease in sensitivity when used as a diagnostic reagent will not be expressed. This is because the edges of the resin tend to dry when the resin is expanded, which is not preferable because crystals tend to form due to the relationship with solubility.

本発明において診断試薬の感度、凝集反応時間等をNf
f1するために1ペニシラミンの他に、例えば塩化プリ
ン、サッカロース等を添加することもらシうる。
In the present invention, the sensitivity of the diagnostic reagent, the agglutination reaction time, etc.
For example, purine chloride, saccharose, etc. may be added in addition to 1 penicillamine to obtain f1.

本発明によれば、ラテックス粒子の凝集反応に際しての
感度が長期間に亘り高感度に保持されると共に、長時間
の保存によっても自己凝集を生じない免疫血清学的診断
試薬が得られる。
According to the present invention, it is possible to obtain an immunoserological diagnostic reagent that maintains high sensitivity during the agglutination reaction of latex particles over a long period of time and does not cause self-aggregation even after long-term storage.

実施例 (1)B型肝炎つィルス表面抗原検出用2テックス試薬
の調整、O,OI 5 Mのリン酸食塩緩衝液(、rt
t、4)中に、粒径が0.46μ鴨のポリスチレンラテ
ックス粒子が2.0重月2チ含有されるように分散させ
たもの(A液)t−Kji製した。
Example (1) Preparation of 2tex reagent for detection of hepatitis B virus surface antigen, O, OI 5M phosphate saline buffer (, rt
t-Kji was prepared by dispersing polystyrene latex particles having a particle size of 0.46 μm in t-Kji (liquid A) to contain 2.0 g of polystyrene latex particles having a particle size of 0.46 μm.

HRs抗原をモルモットに免疫して得られた抗血清から
精製した、抗HB@抗原抗体を含むIjG分画成分を、
0.015Mのリン酸食塩an液(、H7,4)に対し
テ500 pf7pgとなるように溶解させたもの(B
液)を調整した。
IjG fraction components containing anti-HB@antigen antibodies purified from antiserum obtained by immunizing guinea pigs with HRs antigen,
A solution (B
liquid) was adjusted.

このA液、B液を体積比でi : IK混合し、ポリス
チレンラテックス粒子10nJl当シ、前記IjG分画
を250μy感作し37℃で120分間加熱した。
The A and B solutions were mixed at a volume ratio of i:IK, and the IjG fraction was sensitized to 10 nJl of polystyrene latex particles for 250 μy and heated at 37° C. for 120 minutes.

このラテックス懸濁液に更にペニシラミン、防腐剤とし
てアジ化ナトリウムを加え、最終的にポリスチレンラテ
ックス粒子が 1.O重J!:%、ペニシラミン0.5
重員チ、アジ化ナトリウム0.1重jltチを含有する
診断試薬を得た。
Penicillamine and sodium azide as a preservative are further added to this latex suspension to finally form polystyrene latex particles. O heavy J! :%, penicillamine 0.5
A diagnostic reagent containing 0.1 weight percent of sodium azide and 0.1 weight percent of sodium azide was obtained.

(21r&度判定及び保存安定性試験 上記のようにして得られた診断試薬50μtと、精製1
18 s抗原を正常人プール血清で希釈した検体50μ
tとを凝集判定用スライドグラス上で混合し3分後の#
ffftを肉眼で観察し感度を判定した。又、診断試薬
を調整した直後のものと4℃で1年間保存したものにつ
いて感度を比較し保存安定性を評価した。
(21r & degree determination and storage stability test 50 μt of the diagnostic reagent obtained as above and purified 1
50μ sample of 18s antigen diluted with normal human pool serum
# after 3 minutes of mixing on a slide glass for aggregation determination.
The sensitivity was determined by observing ffft with the naked eye. In addition, the storage stability was evaluated by comparing the sensitivity of the diagnostic reagents immediately after preparing them and those stored at 4° C. for one year.

第1表 判断基準 什・・・・・・大きな#!集像が認められる。Table 1 Evaluation criteria You... Big #! Image gathering is observed.

十・・・・・・/J%さな、もしくをよ中程度の凝集像
が認められる。
10.../J% Small or medium agglutination images are observed.

士・・・・・・凝集像が不明瞭である。B: The agglomerated image is unclear.

−・・・・・・凝集像が全く認められず、透明である。-... No agglomerated image was observed and the sample was transparent.

第1表から明らかなように、診断試薬を調整直後のもの
と、1t11整後4℃で1年保存後のものとで杜#!果
像の感度に変化がなく、保存安定性がすぐれていること
が確認された。
As is clear from Table 1, the diagnostic reagents immediately after preparation and those after being stored at 4°C for 1 year after conditioning at 1t11 have the highest quality. It was confirmed that there was no change in the sensitivity of the fruit image, and that the storage stability was excellent.

比較例1 実施例1との比較の為に、実施例1においでペニシラミ
ンが使用式れないものについて同様に試験を行った結果
では4℃で6力抜経過後に精製)Ins抗原濃度がlθ
 μ!7mgの場合に→−に判定された。
Comparative Example 1 For comparison with Example 1, a similar test was conducted on the product in which penicillamine was not used in Example 1, and the results showed that the Ins antigen concentration after purification at 4° C. was 1θ
μ! In the case of 7 mg, it was determined as →-.

この場合のラテックス舷薬は陰性コントレール(n n
 s抗原を含まない正常人血清)に対しても十に判定ち
れるおそれがあシ、診断試薬として使用できないもので
あった。
In this case, the latex port is used as a negative control (n n
There was a risk that the test would be incorrect even for normal human serum (which does not contain s antigen), so it could not be used as a diagnostic reagent.

実施例2 +11 ’)ウマチ因子検出用ラテックス試薬の詞整粒
径が0.20 pmのポリスチレンラテックス粒子をグ
リシン−カセイソーダ緩衝液に分散させたラテックス懸
濁液における、ポリスチレンラテックス粒子107v当
5aoooμyのヒトガンマグロブリンを感作し4℃で
1夜放置した。このラテックス懸濁液にペニシラミン、
牛血清アルブミン、を加え、更に防腐剤としてアジ化ナ
トリウムを加え、最終的にポリスチレンラテックス粒子
0.5重M%、ペニシラミン10.01i量チ、牛血清
アルブミン1、 OM員チ、アジ化ナトリウム0.1重
iチが夫々含有されている診断試薬を得た。
Example 2 +11') Latex reagent for detecting equine factor In a latex suspension in which polystyrene latex particles having a size of 0.20 pm are dispersed in a glycine-caustic soda buffer, 5 aoooμy of human body per 107v of polystyrene latex particles. The cells were sensitized to gamma globulin and left overnight at 4°C. This latex suspension contains penicillamine,
Bovine serum albumin is added, sodium azide is added as a preservative, and finally polystyrene latex particles 0.5% by weight, penicillamine 10.01i, bovine serum albumin 1, OM member, sodium azide 0 Diagnostic reagents each containing .1-fold were obtained.

(2)感度判定及び保存安定性試験 10個の血清検体について実施例1におけると同様にし
て感度判定及び保存安定性試験を行った結果を第2表に
示す。
(2) Sensitivity determination and storage stability test Sensitivity determination and storage stability test were performed on 10 serum samples in the same manner as in Example 1. The results are shown in Table 2.

第 2 表 第2表から明らかなように、診断試薬を811整直後の
亀のと乳1整後4℃で1年間保存後のものとでれ凝#+
像の感度に変化がなく、保存安定性がすぐれていること
が確認された。
Table 2 As is clear from Table 2, the diagnostic reagent was stored at 4°C for 1 year after 811 sterilization and after 1 year of storage at 4°C.
It was confirmed that there was no change in image sensitivity and that storage stability was excellent.

実施例3 (1) CRP検出用ラテックス試薬の詞整粒径が0.
12μmのポリスチレンラテックス粒子をグリシン−カ
セイソーダ緩衝液(pH8,6)に分散させたラテック
ス懸濁液における、ポリスチレンラテックス粒子toI
lv 当り、ヤギ産生の抗ヒ)CRP抗血清からrt製
分離したIjG分画500μりを感作した。
Example 3 (1) The particle diameter of the latex reagent for CRP detection was 0.
Polystyrene latex particles toI in a latex suspension in which 12 μm polystyrene latex particles are dispersed in glycine-caustic soda buffer (pH 8,6)
Per lv, 500 μl of the IjG fraction separated at RT from goat-produced anti-Human CRP antiserum was sensitized.

次いでこのラテックス懸濁液にペニシラミン、サッカロ
ース、牛血清アルブミン、塩化コリン、アジ化ナトリウ
ムを夫々加え、最終的にポリスチレンラテックス粒子0
.8重−JL%、ペニシラミン0.0重重貴チ、サッカ
ロース1,0重量チ、牛血清アルブミン1.0重量チ、
塩化コリン2.s重j1%、アジ化ナトリウムo、 t
 1ft、%が夫々含有されている診断試薬を得た。
Next, penicillamine, sucrose, bovine serum albumin, choline chloride, and sodium azide were added to this latex suspension, and finally polystyrene latex particles were
.. 8-JL%, penicillamine 0.0 weight, sucrose 1.0 weight, bovine serum albumin 1.0 weight,
Choline chloride2. s weight j 1%, sodium azide o, t
Diagnostic reagents containing 1 ft.% and 1 ft., respectively, were obtained.

(2)#1度判定及び保存安定性試験 上記のようにして得られた診断試薬について、$1Mc
upの含有#1度の異なる血清検体について、実施例1
と同様にして感度判定及び保存安定性試験を行った結果
、第3表に示すように保存安定住処すぐれていることが
確認された。
(2) #1 degree determination and storage stability test For the diagnostic reagent obtained as above, $1 Mc
Example 1 for different serum samples containing #1 up
As a result of conducting sensitivity determination and storage stability test in the same manner as above, it was confirmed that the storage stability was excellent as shown in Table 3.

jg3表 比較例3 実施例3との比較の為に、実施例3においてぺ二シ2ミ
ンが除かれている試薬を詞整し、実施例3と同様に感度
判定及び保存安定性試験を行った結果第4表に示すよう
に保存安〜定性の低下を来たすことが認められた。
jg3 Table Comparative Example 3 For comparison with Example 3, the reagent in Example 3 from which penicin-2mine was removed was prepared, and the sensitivity determination and storage stability test were conducted in the same manner as in Example 3. As a result, as shown in Table 4, it was observed that the storage stability to quality deteriorated.

第 4 表 実施例4 (1) CRP検出用ラテックス試薬の調整Rfflカ
0112μのスチレン−スチレンスルホン酸ソーダ共重
合体ラテックス粒子が5.0爪Ji: % (50ff
/a+/)含有されるように、前記共重合体ラテックス
粒子をリン酸食塩緩衝液(、II 6.5 )に分散さ
せたもの(A液)をv4整した。
Table 4 Example 4 (1) Preparation of latex reagent for CRP detection Styrene-sodium styrene sulfonate copolymer latex particles with an Rffl of 0112 μm were 5.0 μm Ji: % (50ff
/a+/) The copolymer latex particles were dispersed in a phosphate saline buffer (, II 6.5 ) (solution A) and adjusted to v4.

ヤギ産生の抗ヒ)CRP抗血清から精を分離したIJG
分画をリン酸食塩緩衝液(、H6,5)に500071
77me溶解したもの(B液)を詞整した。
IJG semen isolated from goat-produced anti-human) CRP antiserum
500071 to phosphate saline buffer (H6,5)
The dissolved 77me (liquid B) was prepared.

前記A液、B液を体積比で1:1に混合し、37℃でt
SO分間攪拌し、前記共重合体ラテックス粒子1oyy
尚、6rlc分1i1jlo00μy′II:l&作さ
ぜた。更にベニシツミン、アジ化ナトリウムをリン酸食
塩緩衝液(、H6,5)の溶液として加え、最終的に前
記共重合体ラテックス粒子が1.0ffit%、ベニシ
ラミツ50重量チ、アジ化ナトリウム0.1重iチを含
有する診断試薬を得た。陶ラテックス粒子の表面荷電密
度L2テックス懸濁液における陰イオンの解離濃度で1
6.4 X I O−7モル/−であった。
The A and B solutions were mixed at a volume ratio of 1:1 and heated at 37°C.
The copolymer latex particles were stirred with SO for 1 oyy.
In addition, 6 rlc minutes 1i1jlo00μy'II:l& was made. Further, Benicitumine and sodium azide were added as a solution in phosphate saline buffer (H6,5), and finally the copolymer latex particles were 1.0 ffit%, 50% by weight of Benicitsumi, and 0.1% by weight of sodium azide. A diagnostic reagent containing the following was obtained. The surface charge density of ceramic latex particles L2 is 1 at the dissociated concentration of anions in the tex suspension.
It was 6.4 X I O-7 mol/-.

(2)熟度判定及び保存安定性試験 ′上記のようにして得られた診断試薬について、精@ 
CRPの含有濃度の具なる血清検体について、実施例1
と同様にして感度判定及び保存安定性試験を行ったとこ
ろ、第5表に示すように保存安定性にすぐれていること
が確認された。
(2) Ripeness determination and storage stability test' Regarding the diagnostic reagent obtained as above,
Example 1 Regarding serum samples with CRP content concentration
Sensitivity determination and storage stability tests were conducted in the same manner as above, and as shown in Table 5, it was confirmed that the product had excellent storage stability.

第 5 表Table 5

Claims (1)

【特許請求の範囲】[Claims] 1、粒径O,OSμmから0.80μmのラテックス粒
子lO〜当シ、ガンマグロブリンが250μりから50
001tf感作されてお、す、該ラテックス粒子が00
8重M係から2.0重−[%含有されているラテックス
懸濁液からな、す、該懸濁液中に0.01重量%から1
000重奇襲のペニシラミンが添加されでいることを特
徴とする免疫血清学的診断試薬。
1. Particle size O, OSμm to 0.80μm latex particles 1O ~ Our gamma globulin is 250μm to 50μm
001tf sensitized, the latex particles are 00
The latex suspension contains from 8 to 2.0% by weight, and from 0.01% to 1% by weight in the suspension.
1. An immunoserological diagnostic reagent characterized in that 000 heavy-duty penicillamine is added.
JP20349182A 1982-11-18 1982-11-18 Reagent for immune serological diagnosis Granted JPS5992354A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP20349182A JPS5992354A (en) 1982-11-18 1982-11-18 Reagent for immune serological diagnosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20349182A JPS5992354A (en) 1982-11-18 1982-11-18 Reagent for immune serological diagnosis

Publications (2)

Publication Number Publication Date
JPS5992354A true JPS5992354A (en) 1984-05-28
JPH0145028B2 JPH0145028B2 (en) 1989-10-02

Family

ID=16475032

Family Applications (1)

Application Number Title Priority Date Filing Date
JP20349182A Granted JPS5992354A (en) 1982-11-18 1982-11-18 Reagent for immune serological diagnosis

Country Status (1)

Country Link
JP (1) JPS5992354A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62218866A (en) * 1986-03-20 1987-09-26 Hitachi Chem Co Ltd Reagent for quantitative analysis of human c-reactive protein
JPS62218864A (en) * 1986-03-20 1987-09-26 Hitachi Chem Co Ltd Quantitative analysis of human c reactive protein
JPS62233759A (en) * 1986-03-28 1987-10-14 エスエイ・テキサコ・ベルジヤン・エヌヴイ Device for continuously measuring ratio of diluted solution to colloidal fluid generating coagulation by mixed liquid ofsaid fluid and said diluted solution
JPS6415656A (en) * 1987-07-09 1989-01-19 Nissui Seiyaku Co Method for quantifying c reactive protein
EP3564676A4 (en) * 2016-12-27 2020-07-22 JSR Corporation Method of storing latex particle dispersion liquid

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62218866A (en) * 1986-03-20 1987-09-26 Hitachi Chem Co Ltd Reagent for quantitative analysis of human c-reactive protein
JPS62218864A (en) * 1986-03-20 1987-09-26 Hitachi Chem Co Ltd Quantitative analysis of human c reactive protein
JPS62233759A (en) * 1986-03-28 1987-10-14 エスエイ・テキサコ・ベルジヤン・エヌヴイ Device for continuously measuring ratio of diluted solution to colloidal fluid generating coagulation by mixed liquid ofsaid fluid and said diluted solution
JPH0833382B2 (en) * 1986-03-28 1996-03-29 エスエイ・テキサコ・ベルジヤン・エヌヴイ probe
JPS6415656A (en) * 1987-07-09 1989-01-19 Nissui Seiyaku Co Method for quantifying c reactive protein
EP3564676A4 (en) * 2016-12-27 2020-07-22 JSR Corporation Method of storing latex particle dispersion liquid

Also Published As

Publication number Publication date
JPH0145028B2 (en) 1989-10-02

Similar Documents

Publication Publication Date Title
US4656144A (en) Immunoparticles and process for preparing same
US4305925A (en) Latex reagent
US4060597A (en) Serological reagent and preparation thereof
DK167618B1 (en) DISPERSION POLYMERS, PROCEDURES FOR THEIR PREPARATION AND THEIR USE
GB2042170A (en) Reagent for tests utilizing latex agglutination
JPS5992354A (en) Reagent for immune serological diagnosis
Kallerup et al. Igg-, igm-and iga-rheumatoid factors in healthy adults and rheumatoid patients determined by an indirect immunofluoroscence method
JP2824794B2 (en) A method to search for and identify erythrocyte antibodies by solid-phase method
JPS5846243B2 (en) Method for producing latex for serological diagnostic reagents
JPS5850646B2 (en) Method for producing latex for serological diagnostic reagents
US9383356B2 (en) Latex particles for particle agglutination assay
JPH1123573A (en) Immunological measuring method
JPH1151938A (en) Immunological latex nephelometry quantifying reagent
JPH07229900A (en) Immunological diagnostic reagent
JP2006227027A (en) Measuring reagent for measured material
JPH01253654A (en) Stable latex reagent
JPS6116942B2 (en)
JPS6116944B2 (en)
US3697639A (en) Serological test for the detection of hepatitis
JPS62138502A (en) Polymer particle
JPH0157688B2 (en)
JP4121400B2 (en) Latex composition for immunoassay
JPS6315553B2 (en)
JP3644704B2 (en) Immunoassay
JPS5834486B2 (en) Method for producing latex for diagnostic reagents